Holen Sie sich die Stockscreener-App
17.60
0.80%
0.14
Handel nachbörslich:
17.56
-0.04
-0.23%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$17.46
Offen:
$17.53
24-Stunden-Volumen:
7.51M
Relative Volume:
0.81
Marktkapitalisierung:
$20.22B
Einnahmen:
$14.57B
Nettoeinkommen (Verlust:
$-296.50M
KGV:
-67.95
EPS:
-0.259
Netto-Cashflow:
$1.64B
1W Leistung:
-1.29%
1M Leistung:
+2.98%
6M Leistung:
+30.95%
1J Leistung:
+74.09%
1-Tages-Spanne:
$17.34
$17.65
1-Wochen-Bereich:
$17.34
$18.43
52-Wochen-Spanne:
$9.69
$18.43
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Compare VTRS vs TAK, TEVA, HLN, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
17.60 | 20.48B | 14.57B | -296.50M | 1.64B | -0.259 |
TAK
Takeda Pharmaceutical Co Adr
|
17.86 | 60.23B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.53 | 45.71B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
8.80 | 40.72B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
69.69 | 29.36B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
541.70 | 20.39B | 3.17B | 1.29B | 1.01B | 27.09 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-09 | Hochstufung | UBS | Neutral → Buy |
| 2026-01-16 | Hochstufung | Argus | Hold → Buy |
| 2025-12-09 | Eingeleitet | Barclays | Overweight |
| 2025-10-15 | Eingeleitet | Truist | Buy |
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Why Viatris (VTRS) is a Top Value Stock for the Long-Term - Zacks Investment Research
Viatris Facing Multiple Paths to Earnings Growth, Oppenheimer Says - Moomoo
Net income before discontinued operations of Viatris, Inc. – HAN:VIA - TradingView
Viatris named to Forbes' World's Best Employers list for sixth year, highlighting strong workplace culture. - Pluang
Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year - PR Newswire
Viatris stock hits 52-week high at 18.4 USD By Investing.com - Investing.com Australia
Viatris stock hits 52-week high at 18.4 USD - Investing.com
Viatris Inc Agencies, 2022 - OpenSecrets
Viatris Inc. stock rises Monday, outperforms market - MarketWatch
Viatris (VTRS) Q1 2026 Earnings Call Transcript - Fortune
Viatris (VTRS) Q2 2026 Earnings Call Transcript - Fortune
Viatris Inc Agencies, 2026 - OpenSecrets
Viatris Inc. stock rises Friday, outperforms market - MarketWatch
Viatris sues Novo Nordisk, seeks to market generic Wegovy - Seeking Alpha
Viatris sues Novo Nordisk over generic Wegovy patent dispute - Yahoo Finance
Viatris sues Novo Nordisk over generic Wegovy patent dispute By Investing.com - Investing.com Canada
Mylan asks US court to clear Wegovy generic from Novo patent claims - reuters.com
Trump seeks to produce more generic drugs in the US - Seeking Alpha
Is Viatris Stock Outperforming the S&P 500? - Yahoo Finance
How Viatris Inc. (VTRS) Affects Rotational Strategy Timing - Stock Traders Daily
Viatris (VTRS) Q4 2025 Earnings Call Transcript - fortune.com
VTRS News | VIATRIS INC (NASDAQ:VTRS) - ChartMill
Viatris, Teva initiated at Outperform at Oppenheimer - Seeking Alpha
Oppenheimer Initiates Viatris at Outperform With $25 Price Target - marketscreener.com
Oppenheimer initiates Viatris stock with outperform rating - Investing.com
Oppenheimer initiates Viatris stock with outperform rating By Investing.com - Investing.com Nigeria
Viatris Inc. (VTRS) Stock Analysis: Exploring A 10.78% Upside With Strategic Collaborations - DirectorsTalk Interviews
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business? - Yahoo Finance
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Piper Sandler raises Viatris stock price target on patch growth - Investing.com
Viatris receives Japan approval for sleep disorder drug Wakix - Investing.com
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome - PR Newswire
Piper Sandler Adjusts Price Target on Viatris to $13 From $12, Keeps Neutral Rating - Yahoo Finance
Viatris, Long Chau launch lipid disorder management campaign - VnExpress International
Viatris (VTRS) Q2 Earnings Preview: What's in the Cards? - Eastern Progress
Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive - Seeking Alpha
VTRS - Finviz
Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy? - Eastern Progress
Leerink Partners Initiates Viatris at Outperform With $20 Price Target - marketscreener.com
Viatris Inc. stock falls Tuesday, underperforms market - MarketWatch
Argus Adjusts Price Target on Viatris to $20 From $18, Keeps Buy Rating - Moomoo
Viatris gets 11% passive stake disclosed by FMR | VTRS SEC FilingForm SCHEDULE 13G/A - Stock Titan
Argus Research Upgrades Viatris(VTRS.US) to Buy Rating, Announces Target Price $20 - Moomoo
Viatris Inc. (VTRS) Stock Analysis: Evaluating the Healthcare Giant’s 9.60% Potential Upside for Investors - DirectorsTalk Interviews
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris - Yahoo Finance
Viatris Inc. (VTRS) Stock Analysis: Exploring Its 13% Upside Potential And Dividend Appeal - DirectorsTalk Interviews
Viatris (VTRS) Faces Fresh Generic Earnings Questions, Is The 12% Discount Enough? - Yahoo Finance
Viatris Inc (VTRS) Shares Fall 3.3% -- GF Value Says Still Overv - GuruFocus
Viatris Inc (VTRS): A Closer Look Behind a 60 GF Score - GuruFocus
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Viatris Inc-Aktie (VTRS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Campbell Paul | See Remarks |
Jun 25 '26 |
Sale |
16.17 |
50,076 |
809,784 |
316,212 |
5.19%
1.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):